Latanoprost Yonsung (Latanoprost)

Latanoprost activates prostaglandin F (FP) receptors in the eye, which remodels the extracellular matrix of the ciliary body. This remodeling enhances the uveoscleral outflow pathway, allowing aqueous humor to drain more efficiently and thereby decreasing intra‑ocular pressure.

The dosing regimen for Latanoprost Yonsung is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the healthcare professional’s instructions.

Safety data for Latanoprost Yonsung in pregnancy and lactation are limited. It is generally advised to avoid use during pregnancy unless the potential benefit outweighs the risk, and to consider the unknown effects on nursing infants before prescribing.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which is often preferred for its once‑daily dosing and strong IOP‑lowering effect. Compared with beta‑blocker or carbonic anhydrase inhibitor drops, prostaglandin analogs typically achieve greater pressure reduction with a convenient dosing schedule.

Latanoprost Yonsung should be stored at room temperature, below 25 °C, in the original packaging. Protect the bottle from light and moisture, and keep it out of reach of children. Do not freeze the product.

The medication is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a small pocket, and place one drop into the eye. Close the eye gently for a few seconds and avoid blinking excessively.

Serious risks include severe eye inflammation (uveitis or iritis), allergic reactions such as swelling or difficulty breathing, paradoxical increase in intra‑ocular pressure, corneal edema, and rare cases of vision loss. Any sudden change in vision or severe eye discomfort should prompt immediate medical evaluation.

Patients with known hypersensitivity to latanoprost or any component of the formulation should avoid use. It is also contraindicated in individuals with active ocular infections, severe inflammation, or those who have had recent ocular surgery without appropriate waiting periods.